USNA Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas

03
Preço $14.82
Capitalização de Mercado (MRQ) $274M
P/E (TTM) -7.1
EPS (TTM) $-2.10
Receita (TTM) $927M
ROE (TTM) -7.4%
Intervalo 52 Semanas $13–$27

USNA Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização

04
intervalo
barras

A granularidade da barra se adapta ao período selecionado — passe o mouse sobre o gráfico para ver a abertura/máxima/mínima/fechamento de uma barra.

Divisões de Ações 3
Data ex Desdobramento Tipo
23 de Novembro de 2016 2-for-1 Para frente
31 de Outubro de 2003 2-for-1 Para frente
4 de Agosto de 1998 2-for-1 Para frente

Sobre USANA Health Sciences, Inc. Common Stock Visão geral da empresa da Wikipedia

05 · wikidata

USANA Health Sciences, Inc., or USANA, is an American direct sales company based in Salt Lake City, Utah. As of 2021, USANA was the 14th largest direct-selling company in the world by revenue. The company manufactures most of its nutritional products, dietary supplements, and skincare products at a Salt Lake City facility. Its products are sold in 25 countries via a network of independent distributors.

History

In 1992, immunologist and microbiologist Myron Wentz moved his diagnostic testing company, Gull Laboratories, from Salt Lake City to West Valley City, Utah, and spun it into USANA Health Services, a multilevel marketing manufacturer of supplements. Beginning in 1993, Dallin A. Larsen served as USANA's vice president of sales (and later as a consultant to USANA's president and special advisor to the board of directors) before founding the MLM beverage company Monavie in 2005. USANA's products are not available through retail channels, and can only be obtained through one of its brand partnersor by direct order through the company.

On 20 February 2007, Barry Minkow, founder of the Fraud Discovery Institute, distributed a 500-page report to officials at the U.S. Securities and Exchange Commission (SEC), the Federal Bureau of Investigation (FBI), and the Internal Revenue Service (IRS) accusing USANA of operating an illegal pyramid scheme. The SEC conducted an investigation into USANA's business practices in March 2007 and found no evidence of wrongdoing, concluding its inquiry with no enforcement action recommended. Minkow acknowledged that he was shorting USANA's shares, hoping to profit from a drop in the stock price. In April 2007, a class action lawsuit was filed alleging that USANA's common stock had been artificially inflated. In August 2007, USANA was notified by the Securities and Exchange Commission (SEC) that its shares were subject to delisting from the NASDAQ due to its Form 10-Q, and was determined to be in compliance that October.

In January 2008, a shareholder suit was filed with allegations that USANA had misled investors about the sustainability of its growth and business model. The cases were dismissed, and the company was cleared by the U.S. Securities and Exchange Commission after an informal inquiry into the allegations, stating that it did "not intend to recommend any enforcement action by the Commission." Later that year, two Canadian USANA distributors were awarded $7 million in damages for their wrongful dismissal from the company. The firm had terminated their positions in 2003 because it believed the distributor had violated the companies' policies and procedures.

USANA filed suits against Minkow and his company claiming defamation and stock manipulation. USANA dropped the defamation suit and in March 2008 U.S. District Judge Tena Campbell threw out four of the five claims brought by USANA against Minkow ruling that USANA's claims violated California's anti-SLAPP law for suing Minkow for fair criticism and that USANA did not show a reasonable probability of winning on those claims. The remaining charge of stock manipulation was settled in July 2008, when USANA and Minkow reached an undisclosed settlement that included the removal of all USANA-related materials from the Fraud Discovery Institute website, a related Chinese website, and YouTube. Minkow also agreed to never trade in USANA's stock again.

In December 2010, USANA completed the application process to transfer its common stock listing from the NASDAQ National Market System, where it had traded since 1996, to the New York Stock Exchange. The transfer became official at the beginning of 2011. It received drug-establishment registration from the Food and Drug Administration to manufacture over-the-counter drugs later that year. In 2012, 91% of product sales were purchased by associates. The company acquired BabyCare Ltd., a China-based prenatal supplement company, in 2013 and announced plans to build a manufacturing facility in the country.

By 2018, USANA had reported record revenue due to growth in the Asia-Pacific region, though it recorded a 7% drop in net sales during its 2019 annual report. USANA has partnered with HealthCorps on health education for children and, in 2019, the USANA Foundation's Kids Eat program opened a facility to pack and distribute food for childhood hunger in the Utah area. In 2026, the Kids Eat program continued efforts to address childhood food insecurity in Utah by providing food bags to students and allowing businesses, families, and other organizations to sponsor participating schools. It was also announced as the official nutritional partner of the Spartan Race endurance brand in the United States. Its sales for the first quarter of 2020 declined by 2.3 percent compared with 2019 numbers.

The USANA Foundation was founded in 2012 and has provided hundreds of millions of meals in more than 45 countries. Their programs include USANA Kids Eat and the USANA Garden Towers.

In February 2019, the Ministry of Commerce in China suspended operations of all multi-level marketing companies and participants to conduct a 100-day review of the country's health foods industry due to exaggerated advertising claims and questionable products in the unregulated sector. Chinese departments initiated "Hundred Days of Action" to clean up the health market, where 49 products from various companies were revoked, 54 food business licenses of various companies were revoked, 90 business licenses of various companies were revoked, and 465 counterfeit and fake dens were destroyed. 85 companies, including BabyCare Ltd., a USANA subsidiary, signed a declaration to self-discipline and regulate operations, with BabyCare speaking at an event hosted by the Chinese government.

In 2024, USANA acquired a 79% stake in children's health and wellness company Hiya Health in a $260 million transaction, making Hiya a subsidiary of USANA. At the time of the acquisition, Hiya had grown to approximately $100 million in annual sales and offered eight children's health products, including multivitamins, probiotics, iron supplements, and immune support products.

Corporate affairs

Leadership

In 2007, USANA faced repeated controversy after members of its board of directors, medical advisory board and several of its executives made false statements regarding their qualifications, including education and licenses.

Founder Myron Wentz was the company's chief executive officer from 1992 until 2008, when his son, Dave Wentz, succeeded him after working in positions such as president, executive vice president, and senior vice president of strategic development. In 2015, USANA announced that the chief executive officer role would be divided between Wentz and Kevin Guest, with the former taking global operations and the latter, field development and sales. Guest was appointed the sole chief executive officer in November 2016.

Operations

USANA, a multilevel marketing company, sells its products primarily through non-employee Brand Partners, as well as through the Internet. The firm's 2010 income disclosure statement defines "associates" as those who are actively building a business, acting as wholesale buyers, or are new distributors. The firm's 2009 SEC 10-K filing distinguishes between associates and preferred customers. Associates are independent distributors of USANA products and also purchase them for personal use. Preferred customers may purchase products at wholesale prices strictly for personal use and are not permitted to resell or distribute them. As of July 2011, the firm had 222,000 active Associates and 68,000 preferred customers. It manufactured 90% of its products at the Salt Lake City headquarters, which produced more than 22 million tablets each week.

Associates may be eligible to receive commissions based on their own product sales as well as through sales made by any new distributors they recruit. According to documentation from USANA corporate, 87 percent of associates fail to make enough from commissions to recover the cost of their qualifying purchases with 67 percent of all associates making no commission; the top 2.31 percent of associates earns 72.2 percent of the company's commissions. According to a 2011 article published by the Salt Lake City Tribune, the firm's FY09 income disclosure statement indicated that the average yearly income of the company's 165,710 associates, which includes those just starting, was $617, while the "top-of-the-pyramid distributors earn an average of $857,865 annually".

USANA sells nutritional, personal care, and food products through Brand Partners and online channels.

USANA classifies Brand Partners and Preferred Customers in its core nutritional business as active customers. There were 387,000 active customers as of January 2026. In 2025, Brand Partners and Preferred Customers each made up about half of all active customers.

Sponsorships

USANA has been a paid sponsor of various athletic organizations. USANA offers an "Athlete Guarantee Program" to select sponsored athletes. The program permits selected participants to enter into an agreement with the company stipulating that, should an athlete enrolled in the program test positive for a banned substance (included in World Anti-Doping Agency regulations) as a result of taking USANA products, the company will compensate the athlete up to two times his or her current annual earnings up to $1 million USD.

In 2006, USANA signed a co-sponsorship agreement with the WTA Tour and extended it in 2011. The agreement provides athletes with nutritional supplements that are guaranteed to conform to the Tour's antidoping policy. As part of the agreement in 2011, USANA donated $1 to Children's Hunger Fund for every ace scored at a WTA tournament beginning at Wimbledon and continuing through the end of the season. USANA provided its products to 40 athletes at the Turin Olympics and worked with various sports organizations, including the Professional Rodeo Cowboys Association.

In 2003, USANA became the title sponsor of the USANA Amphitheatre, an outdoor amphitheatre based in West Valley City, Utah with a seating capacity of 20,000. In May 2012, United Concerts announced a continued naming rights partnership with USANA Health Sciences through March 2018.

In 2020, USANA became the title partner of U.S. Ski & Snowboard's training and education facility, the Center of Excellence. The facility is a training hub used by Olympians, youth athletes, and various international competitions.

In the lead-up to the 2020 Summer Olympics, USANA announced partnerships with USA Swimming and the USA Skateboarding National Team. It was the official multivitamin sponsor of USA Swimming and official nutritional supplement supplier of USA Skateboarding. The partnerships reportedly extended into multi-year agreements.

Products

USANA produces three product lines: USANA Nutritionals (Cellsentials, Optimizers, and Digestion/Detox nutritional supplements), USANA Diet & Energy (Reset meal replacement shakes, protein bars, and Rev3 energy drinks), and Sensé & Celavive personal care (skin care, skin treatment, and hair & body care products).

USANA Essentials were tested in 2011 by ConsumerLab.com in its Multivitamin and Multimineral Supplements Review of 38 leading multivitamin/multimineral products sold in the U.S. and Canada. The Essentials passed ConsumerLab's test, which included testing of selected index elements, their ability to disintegrate in solution per United States Pharmacopeia guidelines, lead contamination threshold set in California Proposition 65, and meeting U.S. Food and Drug Administration (FDA) labeling requirements.

USANA began using InCelligence Technology in August 2016 and registered it as a U.S. trademark in March 2017. The technology is used in the company's CellSentials nutritional supplement system, including its Core Minerals and Vita-Antioxidant products, which USANA markets as using its InCelligence Complex to support cellular protection and renewal. As of 2019, its products are marketed in the United States, Canada, Australia, New Zealand, Hong Kong, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Netherlands, the United Kingdom, the Caribbean, Puerto Rico, Philippines, France, China, Spain, Italy, Germany, Romania, Denmark, Colombia and Indonesia.

Reception

From 2004 to 2006, USANA was named on Forbes "200 Best Small Companies" list. In 2007, a Forbes article quoted industry experts and government officials who had raised questions about the cost of USANA's supplements and its business practices. Radio-Canada later aired an investigative report that examined the company's products, pricing and "misleading income claims" made to potential associates concerning revenue. It included hidden-camera footage of recruitment and other sessions, which found one group of associates appeared to violate the company's policies and distributor agreements. This contrasted with the Canadian legal requirements for multi-level marketing companies to provide clear, frequent and complete information about the revenue of the typical participant. In addition, the same group of associates were filmed making recommendations for using USANA products to treat illnesses including leukemia.

John Cloud, senior writer for Time Magazine, evaluated nutritional supplements in which he took a regimen of USANA pills, protein bars, powder drinks and psyllium fiber as recommended by the company's online evaluation. Cloud took a blood test before starting the products to measure levels of calcium, protein, sodium, cholesterol, glucose, and other substances, and was then tested again five months after starting the supplement regimen, which included 3,000 pills at a cost of $1,200. The follow-up test revealed a change in only two values; a 75% increase in vitamin D levels (attributed to the vitamin D3 supplement Cloud had been taking) and a 28 mg/dl increase in high-density lipoprotein, which could not be accounted for. Cloud also experienced a placebo response where that act of taking the supplements made him feel more vigorous despite no physiological reasons being present. This response also led to a 10-lb weight gain, as the belief that he was more vigorous led him to make poorer dietary decisions—a phenomenon referred to as the "licensing effect".

New Zealand government statistician for the Commerce Commission, Murray H. Smith, who served as an expert witness in every pyramid scheme case brought by the Commission preceding 10 years, opined in 2008 that very few USANA distributors are likely to become wealthy, and stated, "you can make a very strong argument that this could be a pyramid scheme." When asked by the National Business Review to review the firm's business structure and compensation plan, it was Smith's opinion, from a statistical not legal standpoint, that the firm demonstrated a number of characteristics commonly occurring in pyramid schemes including that most members recoup less than what they pay to participate; that those at the top of the structure are more likely to make more than those on the bottom of the structure; and that as the company grows it will become harder to recruit others. Smith also noted the company's significant turnover in distributors making it necessary to continually recruit.

Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗

Wikidata ↗

setorConsumer products indústriaConsumer products funcionários1.570 paísUS

Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS

06
Receita$925M
2016-12-31 → 2026-01-03
EPS$0.58
2016-12-31 → 2026-01-03
Fluxo de caixa livre$9M
2016-12-31 → 2026-01-03
Margem líquida-4.2%
2016-12-31 → 2026-01-03
Avaliação e Proporções 07–12

Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?

Métrica Tendência de 5 anos USNA média 5A Mediana de Pares Veredito
P/E (TTM) -7.1média 5A ≈19.7 ≈19.7 · ·
P/S (TTM) 0.3média 5A ≈1.0 ≈1.0 1.2 Subvalorizado
P/B (MRQ) 0.5média 5A ≈2.3 ≈2.3 2.4 Subvalorizado
Preço / FCF (TTM) -16.8média 5A ≈20.5 ≈20.5 · ·
Preço / Fluxo de Caixa (TTM) -157.2média 5A ≈13.5 ≈13.5 16.8 Valor justo
Preço / Valor Patrimonial Tangível (MRQ) 0.7média 5A ≈3.0 ≈3.0 · ·

A mediana dos pares é calculada em uma base padronizada por métrica e pode não corresponder sempre à base TTM/MRQ mostrada para esta ação.

valor · ≈ média 5A · mediana do setor · veredicto relativo à mediana

Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados

14
Surpresa Média -21.9%
Próximo relatório Out 19, 2026
PeríodoRelatórioEPS ActualEPS est.Surpresa
30 de Junho de 2026 Jul 20, 2026 $-0.07 $0.44 -116.0%
31 de Março de 2026 $0.61 $0.45 35.9%
31 de Dezembro de 2025 $0.60 $0.42 43.5%
30 de Setembro de 2025 $-0.15 $0.48 -131.3%
30 de Junho de 2025 $0.74 $0.55 34.4%
31 de Março de 2025 $0.73 $0.71 2.2%

Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa

15
Demonstração de Resultados 18
Métrica Tendência 202520242023202220212020201920182017201620152014
Revenue $925M$855M$921M$999M$1.19B$1.13B$1.06B$1.19B$1.05B$1.01B$918M$790M
Cost of Revenue $201M$161M$177M$194M$218M$209M$188M$201M$179M$180M$160M$141M
Gross Profit $724M$693M$744M$805M$969M$926M$873M$989M$868M$826M$759M$650M
R&D Expense $11M$12M$11M$12M$11M$11M$10M$10M$9M$9M$6M$5M
SG&A Expense $337M$263M$257M$262M$279M$261M$268M$275M$265M$234M$209M$185M
Operating Expenses $687M$627M$651M$697M$798M$749M$727M$800M$735M$687M$617M$534M
Operating Income $37M$66M$93M$108M$170M$176M$146M$188M$133M$139M$142M$116M
Interest Expense ··$262.0K$192.0K$57.0K$507.0K$66.0K$36.0K$46.0K$444.0K$15.0K$129.0K
Interest Income $2M$11M$10M$4M$3M$3M$5M$4M$2M$1M$1M$500.0K
Other Non-op $3M$-1M$7.0K$-3M$-2M$-571.0K$-335.0K$-1M$-3.0K$-1M$-174.0K$-820.0K
Pretax Income $42M$76M$102M$109M$171M$178M$150M$192M$135M$139M$143M$116M
Income Tax $30M$34M$39M$39M$54M$53M$50M$65M$72M$39M$48M$39M
Net Income $11M$42M$64M$69M$117M$125M$101M$126M$63M$100M$95M$77M
EPS (Basic) $0.58$2.20$3.31$3.60$5.78$5.89$4.44$5.24$2.57$4.14$3.72$2.90
EPS (Diluted) $0.58$2.19$3.30$3.59$5.73$5.86$4.41$5.12$2.53$3.99$3.59$2.80
Shares (Basic) 18,535,00019,103,00019,250,00019,254,00020,146,00021,156,00022,644,00024,105,00024,349,00024,185,00025,460,00026,443,000
Shares (Diluted) 18,574,00019,162,00019,345,00019,310,00020,343,00021,256,00022,818,00024,642,00024,708,00025,047,00026,355,00027,377,000
EBITDA $70M$81M$106M$121M$183M$190M$161M$205M$149M$152M$152M$125M
Balanço Patrimonial 26
Métrica Tendência 202520242023202220212020201920182017201620152014
Cash & Equivalents $158M$182M$330M$288M$240M$312M$235M$214M$247M$176M$143M$111M
Receivables $4M···········
Inventory $103M$70M$61M$67M$98M$90M$69M$82M$63M$65M$66M$45M
Prepaid Expense $23M$28M$26M$29M$27M$23M$26M$33M$30M$37M$35M$35M
Other Current Assets $5M$5M$6M$7M$4M$5M$5M$7M$5M$6M$5M$6M
Current Assets $288M$279M$418M$384M$365M$425M$329M$392M$340M$278M$244M$191M
PP&E (Net) $94M$95M$100M$98M$102M$100M$95M$92M$103M$101M$88M$71M
PP&E (Gross) ··$212M$210M$211M$199M$181M$178M$177M$164M$120M$114M
Accum. Depreciation $135M$130M$129M$125M$122M$116M$105M$96M$86M$76M$71M$64M
Goodwill $138M$144M$17M$17M$18M$17M$17M$17M$17M$17M$17M$18M
Intangibles $133M$152M$30M$32M$30M$31M$30M$32M$35M$34M$38M$41M
Other Non-current Assets $62M$59M$55M$55M$58M$62M$43M$18M$21M$22M$25M$24M
Total Assets $743M$748M$633M$597M$578M$641M$517M$554M$519M$471M$423M$351M
Accounts Payable $17M$12M$10M$11M$14M$18M$13M$10M$12M$9M$10M$8M
Accrued Liabilities $10M$14M$10M·········
Current Liabilities $129M$140M$119M$144M$161M$168M$136M$149M$141M$138M$131M$109M
Capital Leases $12M$10M$5M$8M$10M·$17M·····
Deferred Tax $5M$4M$5M$4M$7M$12M$10M$13M$14M$5M$10M$11M
Other Non-current Liabilities $23M$18M$12M$14M$14M$19M$19M$1M$1M$1M$1M$1M
Total Liabilities $157M$162M$136M·········
Common Stock $18.0K$19.0K$19.0K$19.0K$19.0K$21.0K$22.0K$24.0K$24.0K$24.0K$25.0K$13.0K
Retained Earnings $466M$479M$445M$392M$345M$383M$306M$330M$288M$265M$215M$166M
AOCI $-16M$-23M$-14M$-13M$458.0K$-4M$-14M$-10M$-1M$-12M$-4M$2M
Stockholders' Equity $533M$532M$497M$434M$395M$442M$352M$391M$363M$325M$281M$230M
Liabilities + Equity $743M$748M$633M$597M$578M$641M$517M$554M$519M$471M$423M$351M
Shares Outstanding 18,281,00019,064,00019,130,00019,206,00019,393,00021,038,00021,655,00023,567,00024,024,00024,485,00024,976,00025,266,000
Fluxo de Caixa 16
Métrica Tendência 202520242023202220212020201920182017201620152014
D&A $33M$15M$13M$13M$13M$14M$15M$17M$16M$13M$10M$9M
Stock-based Comp $14M$15M$15M$13M$14M$14M$16M$15M$15M$17M$11M$10M
Deferred Tax $-7M$-7M$-3M$-7M$-3M$-2M$-4M$607.0K$19M$-4M$-3M$-1M
Amort. of Intangibles $19M$2M$2M$2M$1M$1M$1M$2M$1M$2M$900.0K$431.0K
Restructuring $6M$0$0·········
Other Non-cash $-28M$-3M$-18M$15M$-20M$10M$-442.0K$-7M$10M$11M$-2M$11M
Operating Cash Flow $22M$61M$71M$104M$121M$160M$127M$152M$124M$137M$111M$105M
CapEx $14M$10M$14M$10M$13M$15M$17M$11M$13M$33M$24M$20M
Investing Cash Flow $-10M$-213M$-12M$-12M$-14M$-34M$47M$-69M$-13M$-32M$-25M$-16M
Stock Repurchased $28M$9M$12M$25M$178M$57M$150M$105M$50M$65M$61M$139M
Net Stock Activity $-28M$-9M$-12M$-25M$-178M$-57M$-150M$-105M$-50M$-65M$-61M$-139M
Financing Cash Flow $-41M$10M$-14M$-30M$-181M$-59M$-152M$-105M$-50M$-65M$-49M$-113M
Net Change in Cash $-23M$-149M$42M$48M$-72M$78M$20M$-33M$72M$32M$32M$-26M
Taxes Paid $37M$40M$42M·········
Free Cash Flow $9M$51M$56M$94M$108M$145M$110M$141M$111M$104M$88M$85M
Levered FCF ··$56M$93M$108M$145M$110M$141M$111M$104M$88M$85M
Lucratividade 8
Métrica Tendência 202520242023202220212020201920182017201620152014
Gross Margin 78.3%81.1%80.8%80.6%81.6%81.6%82.3%83.1%82.9%82.1%82.6%82.2%
Operating Margin 4.0%7.8%10.1%10.8%14.3%15.6%13.8%15.8%12.7%13.8%15.4%14.7%
Net Margin 1.2%4.9%6.9%6.9%9.8%11.0%9.5%10.6%6.0%9.9%10.3%9.7%
Pretax Margin 4.5%8.9%11.1%10.9%14.4%15.7%14.2%16.1%12.9%13.8%15.5%14.6%
EBITDA Margin 7.6%9.5%11.5%12.1%15.4%16.8%15.2%17.2%14.2%15.1%16.5%15.8%
ROA 1.4%6.1%10.4%11.8%19.1%21.5%18.8%23.5%12.6%22.4%24.5%21.3%
ROE 2.0%7.9%13.2%16.4%29.3%30.0%30.2%30.5%17.2%33.0%37.0%31.2%
ROIC 1.9%6.9%11.7%15.8%29.4%28.0%27.8%31.7%16.9%30.8%33.5%33.4%
Liquidez e Solvência 3
Métrica Tendência 202520242023202220212020201920182017201620152014
Current Ratio 2.22.03.52.72.32.52.42.62.42.01.91.8
Quick Ratio 1.21.32.82.01.51.91.71.41.81.31.11.0
Interest Coverage ··355.2560.52985.8348.12215.05232.02880.5312.29444.1900.0
Eficiência 2
Métrica Tendência 202520242023202220212020201920182017201620152014
Asset Turnover 1.21.21.51.71.92.02.02.22.12.32.42.2
Inventory Turnover 2.32.52.72.32.32.22.52.82.82.82.93.0
Por Ação 5
Métrica Tendência 202520242023202220212020201920182017201620152014
Book Value / Share $29.16$27.91$25.99$22.62$20.37$20.99$16.24$16.60$15.12$13.29$22.49$18.22
Revenue / Share $49.81$44.59$47.61$51.71$58.32$53.38$46.49$48.26$42.39$40.17$69.70$57.74
Cash Flow / Share $1.20$3.18$3.65$5.38$5.96$7.55$5.55$6.17$5.01$5.47$8.46$7.68
Cash / Share $8.66$9.53$17.27$15.02$12.37$14.83$10.84$9.09$10.29$7.18$11.47$8.80
EPS (TTM) $0.58$2.19$3.30$3.59$5.73$5.86$4.41$5.12$2.53$3.99$3.59$2.80
Taxas de Crescimento 9
Métrica Tendência 202520242023202220212020201920182017201620152014
Revenue YoY 8.3%-7.2%-7.8%-15.8%4.6%·······
Revenue CAGR 3Y -2.5%-10.4%-6.7%·········
Revenue CAGR 5Y -4.0%···········
EPS YoY -73.5%-33.6%-8.1%-37.4%-2.2%·······
EPS CAGR 3Y -45.5%-27.4%-17.4%·········
EPS CAGR 5Y -37.0%···········
Net Income YoY -74.4%-34.1%-8.0%-40.5%-6.5%·······
Net Income CAGR 3Y -46.3%-28.8%-20.0%·········
Net Income CAGR 5Y -38.7%···········
Avaliação (TTM) 10
Métrica Tendência 202520242023202220212020201920182017201620152014
Revenue TTM $925M$855M$921M$999M$1.19B$1.13B$1.06B$1.19B$1.05B$1.01B$918M$790M
Net Income TTM $11M$42M$64M$69M$117M$125M$101M$126M$63M$100M$95M$77M
Market Cap $355M$680M$1.03B$1.02B$1.96B$1.62B$1.73B$2.71B$1.78B$1.50B$798M$646M
P/E 33.516.316.214.817.713.218.122.529.315.317.818.3
P/S 0.40.81.11.01.71.41.62.31.71.50.90.8
P/B 0.71.32.12.45.03.74.96.94.94.62.82.8
P / Tangible Book 1.42.92.32.75.74.1······
P / Cash Flow 15.911.214.59.816.210.113.717.814.410.97.26.1
P / FCF 41.713.418.310.918.111.215.719.316.114.49.17.6
Earnings Yield 3.0%6.1%6.2%6.8%5.7%7.6%5.5%4.5%3.4%6.5%5.6%5.5%

Período mais recente à esquerda · valores nulos mostrados como ·

Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos

16
Métrica 2026-01-032024-12-282023-12-302022-12-312022-01-01
Receita $925M $855M $921M $999M $1.19B
Margem Bruta % 78.3% 81.1% 80.8% 80.6% 81.6%
Margem Operacional % 4.0% 7.8% 10.1% 10.8% 14.3%
Lucro líquido $11M $42M $64M $69M $117M
EPS Diluído $0.58 $2.19 $3.30 $3.59 $5.73

Investidores institucionais (13F) 151 declarantes · $260.7M total · Em 30 de Setembro de 2026

17

Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.

Detentores 151
Valor detido $260.7M
Novas posições 25
Posições encerradas 17
Atividade institucional — Q2 2026 vs trimestre anterior
Novas posições Posições encerradas Aumentou Diminuído Variação líquida de ações
25 (-5 vs trimestre anterior) 17 (+8 vs trimestre anterior) 60 (+21 vs trimestre anterior) 30 (-19 vs trimestre anterior) +1.2M

Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.

Instituição Valor Ações % de 13F rastreado Tipo
BlackRock, Inc. $33.181.935 1.554.189 12,73% Ações
PZENA INVESTMENT MANAGEMENT LLC $25.739.282 1.205.587 9,87% Ações
RENAISSANCE TECHNOLOGIES LLC $20.464.402 958.520 7,85% Ações
VANGUARD GROUP INC $18.340.623 934.316 7,03% Ações
DIMENSIONAL FUND ADVISORS LP $17.878.705 837.426 6,86% Ações
Nantahala Capital Management, LLC $17.295.080 810.074 6,63% Ações
VANGUARD CAPITAL MANAGEMENT LLC $10.405.350 487.370 3,99% Ações
Creative Planning $8.923.681 417.971 3,42% Ações
AQR CAPITAL MANAGEMENT LLC $8.712.637 408.086 3,34% Ações
VANGUARD PORTFOLIO MANAGEMENT LLC $7.758.099 363.377 2,98% Ações
GEODE CAPITAL MANAGEMENT, LLC $6.047.019 283.165 2,32% Ações
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $5.811.641 272.208 2,23% Ações
STATE STREET CORP $5.577.474 261.240 2,14% Ações
Nuveen, LLC $5.112.835 239.477 1,96% Ações
AMERICAN CENTURY COMPANIES INC $3.999.880 187.348 1,53% Ações
JACOBS LEVY EQUITY MANAGEMENT, INC $3.855.105 180.567 1,48% Ações
TWO SIGMA INVESTMENTS, LP $3.533.724 165.514 1,36% Ações
MORGAN STANLEY $3.509.150 164.363 1,35% Ações
D. E. Shaw & Co., Inc. $3.348.427 156.835 1,28% Ações
Allianz Asset Management GmbH $3.040.219 142.399 1,17% Ações
BRIDGEWAY CAPITAL MANAGEMENT, LLC $2.949.567 138.153 1,13% Ações
ALGERT GLOBAL LLC $2.813.033 131.758 1,08% Ações
GOLDMAN SACHS GROUP INC $2.631.750 123.267 1,01% Ações
UBS Group AG $2.474.166 115.886 0,95% Ações
LAZARD ASSET MANAGEMENT LLC $2.077.590 97.311 0,80% Ações
NORTHERN TRUST CORP $2.016.870 94.467 0,77% Ações
AMERIPRISE FINANCIAL INC $1.552.893 72.735 0,60% Ações
VANGUARD FIDUCIARY TRUST CO $1.549.540 72.578 0,59% Ações
Vanguard Global Advisers, LLC $1.514.569 70.940 0,58% Ações
Empowered Funds, LLC $1.499.902 70.253 0,58% Ações
TWO SIGMA ADVISERS, LP $1.289.691 65.700 0,49% Ações
Bank of New York Mellon Corp $1.104.521 51.734 0,42% Ações
Quantinno Capital Management LP $1.072.261 50.223 0,41% Ações
BANK OF AMERICA CORP /DE/ $967.539 45.318 0,37% Ações
ROYCE & ASSOCIATES LP $884.039 41.407 0,34% Ações
DEUTSCHE BANK AG\ $821.975 38.500 0,32% Ações
Assenagon Asset Management S.A. $815.848 38.213 0,31% Ações
BARCLAYS PLC $777.141 36.400 0,30% Ações
STRS OHIO $723.765 33.900 0,28% Ações
Skopos Labs, Inc. $673.696 38.563 0,26% Ações
HSBC HOLDINGS PLC $672.758 31.960 0,26% Ações
Invesco Ltd. $670.775 31.418 0,26% Ações
SEI INVESTMENTS CO $641.513 30.047 0,25% Ações
XTX Topco Ltd $625.320 29.289 0,24% Ações
CITADEL ADVISORS LLC $575.617 26.961 0,22% Ações
MILLENNIUM MANAGEMENT LLC $570.728 26.732 0,22% Ações
Verdad Advisers, LP $556.552 26.068 0,21% Ações
Inspire Investing, LLC $512.954 29.362 0,20% Ações
Sanctuary Advisors, LLC $497.113 23.284 0,19% Ações
Man Group plc $489.854 22.944 0,19% Ações

Mostrar todos os 151 proprietários institucionais →

Ativistas e proprietários de 5%+ 3 participações

18

Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.

Declarante Declarado Participação Status Propósito Declaração
Gull Global Limited, Myron W. Wentz ×11 declarações 30 de Março de 2026 40,10% Emenda M&A / venda SEC
Gull Holdings, Ltd., Myron W. Wentz, David A. Wentz, Jacquelyn R. Wentz, Bryan Wentz, Annette Wentz, Paul & Jane Meyer Family Foundation, Paul James Meyer, Alice Jane Meyer, Centre Island Properties, Ltd., Waco Boys Club Foundation, Inc., L-K Marketing Group, LLC, Beagle Irrevocable Asset Trust 23 de Maio de 2008 · Declaração inicial · SEC
Paul & Jane Meyer Family Foundation 20 de Maio de 2008 · Declaração inicial Investimento passivo SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Executivos da empresa 38 insiders · 20 diretores · 13 conselheiros

19
Investidor com informação privilegiada Função Última atividade Ações detidas Compras 12m Vendas 12m Líquido 12m
Jim Brown CEO & PRESIDENT 24 de Julho de 2025 M 16.934 0 0 $0
Doug G Iiekking CHIEF FINANCIAL OFFICER 27 de Maio de 2026 S 0 0 1 $-100.500
Jeffrey Yates Chief Financial Officer 28 de Outubro de 2010 M 0 0 0 $0
Deborah Woo President of Asia 8 de Setembro de 2016 M 1.479 0 0 $0
Fred W Cooper President and COO 28 de Outubro de 2010 M 0 0 0 $0
Walter Noot CHIEF OPERATING OFFICER 27 de Fevereiro de 2026 M 9.256 0 0 $0
Roy Truett Chief Operating Officer 27 de Julho de 2012 M 0 0 0 $0
Kathryn Michelle Armstrong CHIEF SCIENTIFIC OFFICER 25 de Julho de 2026 M 3.471 0 0 $0
Peter Benedict CHIEF INFORMATION OFFICER 25 de Julho de 2026 M 422 0 2 $-144.236
Brent Neidig CHIEF COMMERCIAL OFFICER 16 de Junho de 2026 S 0 0 3 $-147.749
Paul A. Jones CHIEF PEOPLE OFFICER 8 de Junho de 2026 S 0 0 2 $-231.984
Joshua Foukas CHIEF LEGAL OFFICER 7 de Maio de 2026 S 0 0 2 $-170.336
David Mulham Mulham CHIEF SALES OFFICER 10 de Dezembro de 2025 S 8.387 0 1 $-18.333
Daniel A. Macuga CHIEF COMMUNICATIONS OFFICER 2 de Maio de 2024 S 0 0 0 $0
Robert A Sinnott CHIEF SCIENTIFIC OFFICER 5 de Março de 2024 S 0 0 0 $0
James Bramble Chief Legal Officer and Sec 5 de Fevereiro de 2018 A 2.076 0 0 $0
Dave Wentz Co-C.E.O. 16 de Agosto de 2016 M 384.883 0 0 $0
Rick Stambaugh Chief Information Officer 17 de Dezembro de 2015 M 0 0 0 $0
Mark H Wilson E.V.P. of Sales 28 de Outubro de 2010 M 5.000 0 0 $0
Bradford Richardson E.V.P. of Asia Pacific 25 de Fevereiro de 2008 S 0 0 0 $0
Xia Ding Conselheiro 23 de Julho de 2026 M 8.278 0 0 $0
John Turman Fleming Conselheiro 23 de Julho de 2026 M 5.862 0 2 $-78.560
Peggie Pelosi Conselheiro 23 de Julho de 2026 M 6.061 0 0 $0
Scott J Nixon Conselheiro 23 de Julho de 2026 M 11.445 0 0 $0
Frederic J Winssinger Conselheiro 23 de Julho de 2026 M 9.733 0 1 $-38.420
Timothy E Wood Conselheiro 23 de Julho de 2026 M 11.837 0 0 $0
Gilbert A Fuller Conselheiro 23 de Julho de 2026 M 1.632 0 3 $-60.414
Robert Auciaux Conselheiro 9 de Maio de 2022 M 8.092 0 0 $0
Feng Peng Conselheiro 28 de Abril de 2021 M 755 0 0 $0
Myron W. Wentz Conselheiro 4 de Fevereiro de 2019 S 9.865.614 0 0 $0
Jerry G Mcclain Conselheiro 4 de Março de 2016 M 0 0 0 $0
Ronald S Poelman Conselheiro 8 de Fevereiro de 2016 A 0 0 0 $0
Denis E Waitley Conselheiro 3 de Novembro de 2006 M 0 0 0 $0
Gull Global Limited Detentor de 10% 4 de Fevereiro de 2019 S 9.865.614 0 0 $0
GULL HOLDINGS LTD Detentor de 10% 1 de Abril de 2015 J 6.491.110 0 0 $0
Kevin Guest · 27 de Fevereiro de 2026 M 45.381 0 0 $0
Donald R. Williams · 1 de Maio de 2017 A · 0 0 $0
Doug Braun · 16 de Dezembro de 2015 M 0 0 0 $0

Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto

Participação em ETFs Detido por 22 ETFs

20

O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.

Fundo Peso Unidades Em Fonte
VFVA · VANGUARD WELLINGTON FUND 0,11% 45.046 SH 19 de Agosto de 2026 Diário
EBIT · Harbor ETF Trust 0,07% 367 NS 31 de Julho de 2026 N-PORT
IWC · iShares Trust 0,04% 37.870 SH 11 de Setembro de 2026 Diário
VDC · VANGUARD WORLD FUND 0,03% 128.565 SH 19 de Agosto de 2026 Diário
VTWV · VANGUARD SCOTTSDALE FUNDS 0,02% 9.639 SH 19 de Agosto de 2026 Diário
DFSV · Dimensional ETF Trust 0,02% 67.386 NS 31 de Julho de 2026 N-PORT
PRFZ · Invesco Exchange-Traded Fund Trust 0,01% 23.709 SH 2 de Outubro de 2026 Diário
DFAT · Dimensional ETF Trust 0,01% 67.428 NS 31 de Julho de 2026 N-PORT
VTWO · VANGUARD SCOTTSDALE FUNDS 0,01% 64.278 SH 19 de Agosto de 2026 Diário
RSSL · Global X Funds 0,01% 5.337 NS 31 de Julho de 2026 N-PORT
OMFS · Invesco Exchange-Traded Self-Indexe… 0,01% 1.189 SH 1 de Outubro de 2026 Diário
DFAS · Dimensional ETF Trust 0,01% 42.099 NS 31 de Julho de 2026 N-PORT
IWM · iShares Trust 0,01% 283.783 SH 11 de Setembro de 2026 Diário
DFAC · Dimensional ETF Trust 0,00% 19.278 NS 31 de Julho de 2026 N-PORT
ITOT · iShares Trust 0,00% 22.756 SH 11 de Setembro de 2026 Diário
IWV · iShares Trust 0,00% 3.720 SH 3 de Setembro de 2026 Diário
DFUS · Dimensional ETF Trust 0,00% 1.784 NS 31 de Julho de 2026 N-PORT
VXF · VANGUARD INDEX FUNDS 0,00% 124.681 SH 19 de Agosto de 2026 Diário
VTI · VANGUARD INDEX FUNDS 0,00% 350.035 SH 19 de Agosto de 2026 Diário
VTHR · VANGUARD SCOTTSDALE FUNDS 0,00% 790 SH 19 de Agosto de 2026 Diário
IWN · iShares Trust · 101.470 SH 11 de Setembro de 2026 Diário
SMLF · iShares Trust · 22.964 SH 11 de Setembro de 2026 Diário

USNA Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta

21
classificação · 6 analistas VENDA
Alvo mediano $25.00 +68,7%
0 0,0% Compra forte
0 0,0% Compra
3 50,0% Manter
1 16,7% Venda
2 33,3% Venda forte

Preço-alvo de 12 meses

1 analistas · 2026-10-01

Alvo médio $25.00 +68,7%

Mín$25.00 Média$25.00 Máx$25.00

Comparação de pares (subindústria GICS) Métricas chave vs pares do setor

22

Base do ano fiscal, preços no fechamento do último ano fiscal de cada empresa.

Ticker Capitalização de Mercado P/E Receita YoY Margem Líquida ROE Margem Bruta
USNA $355M 33.5 8.3% 1.2% 2.0% 78.3%
EPC $946M 38.4 -1.3% 1.1% 1.7% 41.6%
BRBR $4.39B 21.6 16.1% 9.3% -72.0% 33.3%
HNST $291M -18.4 -1.9% -4.2% -8.8% 33.3%
NUS · 3.0 -14.3% 10.8% 22.0% 69.5%
NAGE $507M 31.8 29.9% 13.4% 24.7% 64.3%
NATR $378M 20.4 5.7% 4.1% 12.0% 72.4%
MED $117M -6.3 -36.0% -4.8% -9.0% 71.3%

Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos

26

Escolha as métricas que importam para si — clique no + ao lado de qualquer linha em Fundamentos Completos acima.

Sua seleção é salva e acompanha você em todos os tickers.

Fonte: SEC 10-Q arquivado Ago 13, 2026